Deucravacitinib (Sotyktu): TYK2 Inhibitor Guide for Plaque Psoriasis Treatment

　　Deucravacitinib(brand name Sotyktu)is an oral,highly selective tyrosine kinase 2(TYK2)inhibitor specifically designed to target the pathological mechanisms of psoriasis,and has emerged as a key core option in the systemic treatment of plaque psoriasis in recent years.By selectively inhibiting the TYK2 signaling pathway,the drug precisely interferes with the signal transduction of key pro-inflammatory cytokines including IL-23 and IL-12,fundamentally blocking the inflammatory cascade triggered by excessive immune system activation,thereby achieving sustained improvement of skin lesions.

　　The core approved indication of deucravacitinib is plaque psoriasis.It is currently approved in multiple countries and regions worldwide for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy,providing a novel treatment pathway beyond traditional systemic therapies and biologic agents.

　　In terms of clinical efficacy,deucravacitinib demonstrates the dual advantages of rapid onset in the short term and sustained stability in the medium to long term.Short-term treatment data show that within the 12-week standard treatment cycle,patients achieve a significant improvement in the Psoriasis Area and Severity Index(PASI),with a significantly superior skin lesion clearance effect compared to the placebo control group.In long-term extension studies,the durability of the drug's efficacy has been fully verified:continuous standard treatment can stably maintain the improvement of skin lesions,and the stability of efficacy over 2 years,3 years and even longer cycles has been confirmed in multiple global multicenter extension trials.

　　Compared with existing systemic treatment regimens for psoriasis,deucravacitinib has clear clinical advantages.Data from multiple clinical studies show that the drug is significantly superior to the traditional oral treatment apremilast in improving the core efficacy endpoints of psoriasis,and demonstrates a more prominent effect especially in the improvement of some refractory skin lesions.Meanwhile,as an oral small-molecule drug,it provides patients with a non-injectable,non-biologic treatment option,eliminating the need for in-hospital infusion or home injection procedures,and has an inherent advantage in improving patients'long-term treatment adherence.

　　It should be noted that although the overall efficacy of the drug is significant,there are individual differences in the degree of treatment response among different patients,which are related to various factors such as the duration of the disease,personal constitution,and comorbid underlying diseases.Long-term clinical follow-up data of up to 5 years confirm that deucravacitinib has a controllable overall safety profile while maintaining the effect of improving skin lesions for a long time,providing solid evidence-based support for the long-term full-course management of psoriasis.

　　Overall,deucravacitinib demonstrates clear clinical efficacy and favorable tolerability in the treatment of moderate-to-severe plaque psoriasis,along with the potential for sustained long-term improvement of skin lesions,making it an important breakthrough option in the field of systemic psoriasis treatment.